NX-2127 inhibits the proliferation of BTK-C481S mutant TMD8 cells with an EC50 value of <30 nM.[1]
NX-2127 increases IL-2 production in primary human T cells.[1]

NX-2127 (1 mg/kg; oral; once daily for 14 days) showed efficient degradation of BTK in cynomolgus monkeys.[1]
NX-2127 (oral administration) results in dose-proportional exposure and degradation of BTK in plasma to less than 10% of baseline levels in circulating and splenic B cells.[1]
NX-2127 produces superior tumor growth inhibition (TGI) in WT TMD8 and C481S mutant xenograft models in mice.[1]